Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Regeneron Gains 13.5% Year to Date: How to Play the Stock?
Pharmaceutical company warns: if muscle loss issue is not addressed, 'miracle weight-loss drugs' may do more harm than good.
①USA pharmaceutical company Regeneron stated that current GLP-1 weight loss drugs can lead to rapid muscle loss, and the company is developing a weight loss drug that can overcome this flaw; ② Regeneron warned that if the muscle loss issue is not resolved, GLP-1 weight loss drugs may do more harm than good.
Regeneron Sees $56M Pretax Charge Hitting 3Q Earnings
Regeneron Sees IPR&D Impact of About $0.43/share on Q3 Income
Express News | Regeneron Pharmaceuticals - Expects Q3 Results Will Include Acquired Ipr&D Charge of Sbout $56 Mln on Pre-Tax Basis
Regeneron Co-founder Warns of Harms From Weight-loss Drugs: FT
Regeneron Pharma Is Maintained at Outperform by RBC Capital
Regeneron Pharmaceuticals Analyst Ratings
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing
Market Whales and Their Recent Bets on REGN Options
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks